Overview of bladder cancer trials in the Cancer and Leukemia Group B Journal Article
| Authors: | Small, E. J.; Halabi, S.; Dalbagni, G.; Pruthi, R.; Phillips, G.; Edelman, M.; Bajorin, D. |
| Article Title: | Overview of bladder cancer trials in the Cancer and Leukemia Group B |
| Abstract: | The Cancer and Leukemia Group B (CALGB) Genitourinary Committee has developed a broad range of clinical trials across most stages of bladder cancer. Recurrence rates of superficial bladder cancer after transurethral resection range from 50-70%. Although adjuvant bacillus Calmette-Guerin reduces the risk of disease recurrence or progression, only 30% of patients have long-term disease-free survival. Because the development of novel secondline agents is needed, the CALGB is evaluating the utility of intravesicle gemcitabine as well as an oral proapoptotic agent (CP-461). In patients with locally advanced disease with an increased risk of disease recurrence after cystectomy, a randomized trial of conventional chemotherapy versus sequential dose-dense therapy is under development. The gemcitabine/cisplatin combination has become a commonly used regimen for the treatment of advanced transitional cell carcinoma (TCC). The CALGB is undertaking a Phase II study that incorporates a fixed dose rate gemcitabine infusion in this regimen, together with a selective epidermal growth factor receptor tyrosine kinase inhibitor, Iressa (Astra Zeneca, Wilmington, DE). In patients with renal insufficiency, a regimen of carboplatin, gemcitabine, and Iressa is planned. Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy. © 2003 American Cancer Society. |
| Keywords: | cancer survival; leukemia; clinical trial; neutropenia; cancer recurrence; salvage therapy; cisplatin; doxorubicin; cancer combination chemotherapy; cancer risk; side effect; conference paper; skin manifestation; gemcitabine; paclitaxel; cancer patient; methotrexate; antineoplastic agent; bcg vaccine; carboplatin; infection; pain; mucosa inflammation; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; epidermal growth factor receptor; kidney failure; antineoplastic activity; bladder cancer; urinary bladder neoplasms; ifosfamide; vinblastine; protein tyrosine kinase inhibitor; drug receptor binding; febrile neutropenia; hyperglycemia; postoperative complication; arsenic trioxide; cystectomy; gefitinib; toxicity; trastuzumab; transurethral resection; carcinoma, transitional cell; bladder carcinoma; transitional cell carcinoma; clinical trials; oncogene neu; weight gain; bladder metastasis; retinoic acid syndrome; humans; human; priority journal; cp 461; gemcitabine/cisplatin combination |
| Journal Title: | Cancer |
| Volume: | 97 |
| Issue: | 8 Suppl. |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2003-04-15 |
| Start Page: | 2090 |
| End Page: | 2098 |
| Language: | English |
| PUBMED: | 12673701 |
| PROVIDER: | scopus |
| DOI: | 10.1002/cncr.11299 |
| DOI/URL: | |
| Notes: | Based on a Satellite Symposium held in conjunction with the First European Conference on Perspectives in Bladder Cancer; 2001 Nov 16-17; Monte Carlo, Monaco -- Export Date: 25 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work